Quick Answer
Prelude Therapeutics Inc reported Earnings Per Share Diluted of $1.29 (loss) per share for the year ending 2025.
- Prelude Therapeutics Inc showed an increase of +23.2% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Prelude Therapeutics Inc's annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), Prelude Therapeutics Inc's Earnings Per Share Diluted has grown by 46.9%.
- Historical annual values: Fiscal year 2025: $1.29 (loss) per share | Fiscal year 2024: $1.68 (loss) per share | Fiscal year 2023: $2.02 (loss) per share | Fiscal year 2022: $2.44 (loss) per share | Fiscal year 2021: $2.43 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: